AOLS (Aeolus Pharmaceuticals) Current Deferred Revenue: $0.00 Mil (As of Jun. 2017)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Aeolus Pharmaceuticals Current Deferred Revenue?

Aeolus Pharmaceuticals AOLS Current Deferred Revenue is $0.00 Mil as of Jun. 2017.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Aeolus Pharmaceuticals's current deferred revenue for the quarter that ended in Jun. 2017 was $0.00 Mil.

Aeolus Pharmaceuticals Current Deferred Revenue Related Terms

Aeolus Pharmaceuticals Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Aeolus Pharmaceuticals's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aeolus Pharmaceuticals Current Deferred Revenue Chart

Aeolus Pharmaceuticals Annual Data
Trend Sep07 Sep08 Sep09 Sep10 Sep11 Sep12 Sep13 Sep14 Sep15 Sep16
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.11 0.68 0.44 0.02 0.00

Aeolus Pharmaceuticals Quarterly Data
Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.00 0.00 0.00 0.00
What does a Current Deferred Revenue of $0.00 Mil mean?
Aeolus Pharmaceuticals (AOLS) has a Current Deferred Revenue of $0.00 Mil as of Jun. 2017. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Aeolus Pharmaceuticals and its competitors.
Is Aeolus Pharmaceuticals' Current Deferred Revenue too high?
Aeolus Pharmaceuticals' current Current Deferred Revenue is $0.00 Mil.
How does Aeolus Pharmaceuticals' Current Deferred Revenue compare to RDGL and PCYN?
Aeolus Pharmaceuticals' Current Deferred Revenue of $0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Drug Manufacturers company?
A good Current Deferred Revenue depends on the Drug Manufacturers industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Aeolus Pharmaceuticals and its competitors. Aeolus Pharmaceuticals's current Current Deferred Revenue is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aeolus Pharmaceuticals stock overvalued right now?
Aeolus Pharmaceuticals (AOLS) has a current Current Deferred Revenue of $0.00 Mil. The current Current Deferred Revenue is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Aeolus Pharmaceuticals (AOLS), the current Current Deferred Revenue is $0.00 Mil as of Jun. 2017. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aeolus Pharmaceuticals Business Description

Address 26361 Crown Valley Parkway, Suite 150, Mission Viejo, CA, USA, 92691
Aeolus Pharmaceuticals Inc is a Southern California-based biopharmaceutical company. The company is developing a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious disease and diseases of the central nervous system. Aeolus is developing its lead compound, AEOL-10150, as a treatment for the lung effects of Acute Radiation Syndrome (Lung-ARS). Aeolus also has two pre-clinical development programs: AEOL 11114 and AEOL 20415.